Sickle cell disease and Hydroxyurea

Deep Dive

Sickle cell disease stems from a single beta‑globin mutation that promotes hemoglobin S polymerization, red cell deformation, and a cascade of h... Sickle cell disease stems from a single beta‑globin mutation that promotes hemoglobin S polymerization, red cell deformation, and a cascade of hemolysis, inflammation, and vaso‑occlusion. Clinically, this presents as recurrent painful crises, acute chest syndrome, stroke risk, and progressive organ injury. Hydroxyurea is the longest‑standing disease‑modifying therapy with robust evidence across ages. Its central action is induction of fetal hemoglobin (HbF), which dilutes HbS and inhibits polymer formation. Secondary effects—macrocytosis, reduction of leukocytes and reticulocytes, and dampening of adhesion and inflammatory mediators—contribute to improved rheology and endothelial function. Randomized trials established efficacy for reducing painful crises and acute chest syndrome, while pediatric data demonstrate decreased hospitalizations and transfusions. In carefully selected children transitioned from chronic transfusions, hydroxyurea can maintain transcranial Doppler velocities used for primary stroke prevention, though transfusion remains standard for those with cerebrovascular disease. Observational cohorts link hydroxyurea to better survival, supporting its status as a cornerstone therapy. Safety is well characterized: dose‑related myelosuppression requires regular complete blood count monitoring and clinical follow‑up, particularly during initiation and titration. Non‑hematologic adverse effects are usually mild. Fertility and pregnancy considerations warrant shared decision‑making; emerging human data are reassuring but incomplete, and many guidelines advise avoiding hydroxyurea during conception attempts and pregnancy when alternatives exist. No definitive carcinogenic signal has emerged in SCD populations, but ongoing pharmacovigilance is prudent. In practice, hydroxyurea is initiated in most children and considered broadly in adults with recurrent crises, acute chest syndrome, or significant hemolysis/anemia. It integrates with transfusion programs, iron chelation when needed, and newer agents—voxelotor, crizanlizumab, and L‑glutamine—chosen to target anemia, adhesion, or oxidative stress in patients with residual morbidity. Curative options (hematopoietic stem cell transplant and gene therapy) change the trajectory for a subset, but hydroxyurea remains widely relevant given feasibility, cost, and decades of experience.